Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 3/20 | 0.55 |
| ▸ | GRB2 | P62993 | 1/20 | 0.50 |
| ▸ | F2 | P00734 | 1/20 | 0.49 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.47 |
| ▸ | OPRD1 | P41143 | 6/20 | 0.46 |
| ▸ | NRP1 | O14786 | 1/20 | 0.46 |
| ▸ | NTSR2 | O95665 | 2/20 | 0.45 |
| ▸ | NTSR1 | P30989 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1247726 | 0.89 | GRB2 (0.61) | APLNRGRB2F2CAPN1NRP1 | |
| SCHEMBL31437195 | 0.88 | APLNR (0.46) | APLNR | |
| SCHEMBL29392602 | 0.86 | GRB2 (0.66) | APLNRGRB2F2CAPN1NRP1 | |
| SCHEMBL10783008 | 0.83 | ACE (0.53) | — | |
| SCHEMBL8760024 | 0.83 | ACE (0.53) | — | |
| SCHEMBL8760014 | 0.83 | ACE (0.53) | — | |
| SCHEMBL10782979 | 0.83 | ACE (0.53) | — | |
| SCHEMBL29362706 | 0.83 | GRB2 (0.67) | APLNRGRB2F2CAPN1NRP1 | |
| SCHEMBL31437176 | 0.83 | APLNR (0.49) | APLNR | |
| SCHEMBL30471913 | 0.82 | OPRM1 (0.48) | APLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 229 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250312463-A1 | AUGMENTED PEPTIDE COMPOSITIONS AND METHODS | Neo7Bioscience, Inc. (US) | 2025-10-09 | — | — | US | claimed |
| WO-2025037993-A1 | DOSAGE FORM FOR PEPTIDE AGENTS | MAJEWSKI FILIP (PL) | 2025-02-20 | — | — | WO | claimed |
| US-12161687-B2 | Compositions targeting the interaction domain between p27KIP1 and Brk and methods of use thereof to inhibit p27 Y phosphorylation and cdk4 activity | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2024-12-10 | — | — | US | claimed |
| CN-117860921-A | Application of thymic pentapeptide derivative TP-7 in preparation of tumor diagnosis and/or treatment reagent | 江西中医药大学 | 2024-04-12 | — | — | CN | claimed |
| CN-111184856-B | Application of small molecule polypeptide TP-7 in preparation of medicine for treating chronic kidney disease | 南方医科大学南方医院 | 2023-12-01 | — | — | CN | claimed |
| US-20230293643-A1 | BRK PEPTIDES AND METHODS OF USE | CONCARLO THERAPEUTICS, INC. | 2023-09-21 | — | — | US | claimed |
| EP-4175659-A2 | BRK PEPTIDES AND METHODS OF USE | Concarlo Holdings, LLC (US) | 2023-05-10 | — | — | EP | claimed |
| CN-115867675-A | Nucleic acid sequencing method | 萨摩尔股份有限公司 | 2023-03-28 | — | — | CN | claimed |
| US-20230053231-A1 | COMPOSITIONS TARGETING THE INTERACTION DOMAIN BETWEEN P27KIP1 AND BRK AND METHODS OF USE THEREOF TO INHIBIT P27 Y PHOSPHORYLATION AND CDK4 ACTIVITY | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2023-02-16 | — | — | US | claimed |
| CN-113082202-B | Composite water-soluble animal vaccine adjuvant, vaccine and preparation method of vaccine | 青岛农业大学 | 2022-05-17 | — | — | CN | claimed |
| CN-114177314-A | Application of thymopentin and derivatives thereof in preparation of tumor diagnosis and/or treatment reagent | 江西中医药大学 | 2022-03-15 | — | — | CN | claimed |
| CN-116850307-B | Application of polypeptide TP-6 in preparation of tumor diagnosis and/or treatment reagent | JIANGXI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE (CN) | 2026-05-26 | — | — | CN | disclosed |
| CN-122071534-A | Fusion protein, conjugate containing same, kit and application | 菲鹏生物股份有限公司 | 2026-05-22 | — | — | CN | disclosed |
| WO-2026107393-A2 | AAV CAPSID MODIFICATIONS THAT REDUCE IMMUNOGENICITY | THE BROAD INSTITUTE, INC. (US) | 2026-05-21 | — | — | WO | disclosed |
| US-20260130877-A1 | TREATMENT OF NEURODEVELOPMENTAL DISORDERS | THE REGENTS OF THE UNIV OF CALIFORNIA (US) | 2026-05-14 | — | — | US | disclosed |
| US-20220073589-A1 | GPR156 Variants And Uses Thereof | REGENERON PHARMACEUTICALS, INC. | 2022-03-10 | — | — | US | disclosed |
| US-11266989-B2 | Immunodetection and separation on nanoDLD | INTERNATIONAL BUSINESS MACHINES CORPORATION (US) | 2022-03-08 | — | — | US | disclosed |
| US-11266711-B2 | Oxytocin compositions and methods of use | ELGAN PHARMA LTD (IL) | 2022-03-08 | — | — | US | disclosed |
| WO-2022040612-A1 | INJECTABLE HYDROGELS AND METHODS OF CAPTURING CELLS USING THE SAME | VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY (US) | 2022-02-24 | — | — | WO | disclosed |
| WO-2022020616-A1 | ENGINEERED MUSCLE TARGETING COMPOSITIONS | THE BROAD INSTITUTE, INC. (US) | 2022-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260130877-A1 | TREATMENT OF NEURODEVELOPMENTAL DISORDERS | EED, ICOS, FABP7 | APLNR 2555/4885GRB2 1725/4885F2 1651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.